News

TET Systems (TSH), the Academic Medical Center (AMC), and Technology Foundation STW have entered into an assignment agreement. Scientists at the AMC have previously developed a series of

Ipsen has announced that its partner Roche has disclosed the results of the second and third of eight T-emerge phase III studies in patients with diabetes for Taspoglutide.

Ablynx is expected to receive further milestone payments of E3m from Boehringer Ingelheim, triggered as part of its strategic alliance for the development and commercialisation of nanobodies. Ablynx

Peregrine Pharmaceuticals (Peregrine) has completed patient enrollment in a dose confirmation and dosimetry trial of Cotara in patients with relapsed glioblastoma multiforme (GBM). Cotara is a targeted monoclonal

Hana Biosciences has completed enrollment of its pivotal Phase 2 rALLy clinical trial for Marqibo (vincristine sulfate liposomes injection) for the treatment of adult acute lymphoblastic leukemia (ALL)

Impax Laboratories has entered into a supply agreement with Resolution Chemicals to receive finished Dronabinol product. The company also reported that it has acquired Abbreviated New Drug Applications

CytRx has been permitted to re-enter the clinic with its orally administered molecular chaperone drug candidate Arimoclomol as a therapeutic treatment for amyotrophic lateral sclerosis (ALS or Lou

GSK has completed the extension of its strategic relationship with Aspen Pharmacare (Aspen) and the acquisition of a minority shareholding in the South African based pharmaceuticals company on

Pfizer and Protalix have entered into an agreement to develop and commercialise Taliglucerase Alfa, a plant-cell expressed form of glucocerebrosidase (GCD) in development for the potential treatment of